Joilton Lutterbach won’t make the walk to the octagon in any case, as he’s been released from his UFC contract following a failed drug test that canceled his promotional debut.
Combat Sports Anti-Doping, which handles the UFC anti-doping program together with Drug Free Sport International, announced the news of Lutterbach’s release and acceptance of a 24-month suspension Tuesday.
Lutterbach (38-10) was speculated to make his UFC debut against Shara Magomedov in June. Nevertheless, Lutterbach tested positive for the presence of 3a-Hydroxy-2a-methyl-5a-androstan-17-one, a metabolite of drostanolone, an anabolic steroid that’s prohibited in any respect times. The failed test got here from a urine sample collected by DFSI on June 8 after he signed a bout agreement in May.
Lutterbach admitted that he used performance-enhancing drugs prior to signing with the UFC, but only after his failed test. Athletes who sign with the UFC are required to declare any use of prohibited substances upon being added to the anti-doping program, and might be required to attend 180 days and supply at the very least two negative samples before they might be booked to fight. Lutterbach made no declaration of his drostanolone use in time and due to this fact was handed the two-year sanction and released.
Lutterbach, who fights out of Germany, competed across several combat sports. He’s currently on a three-fight winning streak in MMA, along with his most up-to-date loss coming against Clay Collard under the PFL banner in 2021. Lutterbach has competed for a lot of notable MMA promotions resembling the PFL, Brave, Cage Warriors, and ACB.
He’s competed 3 times in 2024, once in boxing and twice for Karate Kombat.
Make sure you visit the MMA Junkie Instagram page and YouTube channel to debate this and more content with fans of mixed martial arts.
